Serological analysis of human renal cell carcinoma

被引:18
作者
Devitt, G
Meyer, C
Wiedemann, N
Eichmüller, S
Kopp-Schneider, A
Haferkamp, A
Hautmann, R
Zöller, M
机构
[1] German Canc Res Ctr, Dept Infect & Canc, Skin Canc Unit, D-69120 Heidelberg, Germany
[2] German Canc Res Ctr, Dept Tumor Progress & Immune Def, D-69120 Heidelberg, Germany
[3] German Canc Res Ctr, Dept Stat, D-69120 Heidelberg, Germany
[4] Ruprecht Karls Univ Heidelberg, Univ Hosp, Dept Urol, D-69115 Heidelberg, Germany
[5] Univ Ulm, Univ Hosp, Dept Urol, D-89075 Ulm, Germany
[6] Univ Karlsruhe, Dept Appl Genet, D-76128 Karlsruhe, Germany
关键词
human renal cell carcinoma; SEREX; SADA; cancer-testis antigen; immunome;
D O I
10.1002/ijc.21626
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Serological analysis of cDNA expression libraries (SEREX) has proven to be a useful technique in the quest to elucidate the repertoire of immunogenic gene products in human cancer. We have applied the SEREX method to human renal cell carcinoma (RCC) in order to identify associated immunogenic gene products. cDNA expression libraries were prepared from a RCC tumor, a RCC cell line and human testis. The 3 libraries were screened with sera from 35 RCC patients and 15 healthy controls. Approximately 4.5 x 10(6) phage plaques were screened resulting in 234 positive clones, which corresponded to 74 different gene products. The seroreactivity toward 49 of these antigens was assessed. Seroreactivity to 21 (43%) of the antigens was similar in RCC patients and healthy controls, 9 antigens (18%) elicited antibodies more frequently and 19 antigens (39%) solely in RCC patients. In the reverse setting, reactivity of RCC patients' sera was tested against a panel of 44 previously identified "tumor-associated" antigens via the SADA (serum antibody detection array) method; 6 antigens reacted with RCC patients' and healthy donors' sera, 8 were reactive only with RCC patients' sera. From the 27 antigens identified by SEREX and SADA, which did not react with sera from healthy controls, 10 antigens reacted with a significant proportion of RCC patients' sera and 77% of RCC patients' sera reacted at least with one of these antigens. Sera from patients with nonmalignant renal diseases or an autoimmune disease did not react with these 10 antigens. (c) 2005 Wiley-Liss, Inc.
引用
收藏
页码:2210 / 2219
页数:10
相关论文
共 68 条
[1]  
[Anonymous], P NATL ACAD SCI USA
[2]   PLU-1 nuclear protein, which is upregulated in breast cancer, shows restricted expression in normal human adult tissues: A new cancer/testis antigen? [J].
Barrett, A ;
Madsen, B ;
Copier, J ;
Lu, PJ ;
Cooper, L ;
Scibetta, AG ;
Burchell, J ;
Taylor-Papadimitriou, J .
INTERNATIONAL JOURNAL OF CANCER, 2002, 101 (06) :581-588
[3]  
Beisland C, 2004, Scand J Surg, V93, P97
[4]   A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening [J].
Chen, YT ;
Scanlan, MJ ;
Sahin, U ;
Tureci, O ;
Gure, AO ;
Tsang, SL ;
Williamson, B ;
Stockert, E ;
Pfreundschuh, M ;
Old, LJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (05) :1914-1918
[5]   Prolonged upregulation of the expression of HLA class I antigens and costimulatory molecules on melanoma cells treated with 5-aza-2′-deoxycytidine (5-AZA-CdR) [J].
Coral, S ;
Sigalotti, L ;
Gasparollo, A ;
Cattarossi, I ;
Visintin, A ;
Cattelan, A ;
Altomonte, M ;
Maio, M .
JOURNAL OF IMMUNOTHERAPY, 1999, 22 (01) :16-24
[6]   IDENTIFICATION OF A PEPTIDE RECOGNIZED BY 5 MELANOMA-SPECIFIC HUMAN CYTOTOXIC T-CELL LINES [J].
COX, AL ;
SKIPPER, J ;
CHEN, Y ;
HENDERSON, RA ;
DARROW, TL ;
SHABANOWITZ, J ;
ENGELHARD, VH ;
HUNT, DF ;
SLINGLUFF, CL .
SCIENCE, 1994, 264 (5159) :716-719
[7]   Involvement of valosin-containing protein, an ATPase co-purified with IκBα and 26 S proteasome, in ubiquitin-proteasome-mediated degradation of IκBα [J].
Dai, RM ;
Chen, EY ;
Longo, DL ;
Gorbea, CM ;
Li, CCH .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (06) :3562-3573
[8]  
de Riese W, 1991, Int Urol Nephrol, V23, P13
[9]  
Dong XW, 1998, ARTHRITIS RHEUM-US, V41, P1505, DOI 10.1002/1529-0131(199808)41:8<1505::AID-ART23>3.0.CO
[10]  
2-N